In advanced stage ovarian cancer (with FIGO stage III, IV), the value was found to be 5.01 ± 1.05 (as per the TNM grade i.e., Grade-3, measured 4.89 ± 1.16)(Table 2).The difference was found to be statistically significant (p < 0.05) when compared to early stage (FIGO Stage I, II and TNM grade 1,2), suggesting the potential role of serum LOX levels in differentiating the ovarian cancer cases from healthy controls as well as the disease severity. This evidence concerns the gene LOX and ovarian cancer.